The path to a better biomarker: application of a risk management framework for the
implementation of PD-L1 and TILs as immuno-oncology biomarkers into breast cancer
clinical trials and daily practice

Paula I Gonzalez-Ericsson17, Elisabeth S Stovgaard2, Luz Sua3, Emily Reisenbichler4, Zuzana Kos
5 Jodi M Carter6, Stefan Michiels7, John Le Quesne8,9, Torsten O Nielsen10, Anne-Vibeke
Lønkholm11, Stephen Fox12,11, Julien Adam14, John Bartlett15,16, David L Rimm14, Cecily Quinn17,
Dieter Peeters18,19, Maria V Dieci20,21, Anne Vincent-Salomon22, Ian Cree23, Akira I Hida24, Justin
Balko1,25,26, Harry R Haynes27,28, Isabel Frahm29, Gabriela Acosta-Haab30, Marcelo Balancin31,
Enrique Bellolio32, Wentao Yang33, Pawan Kirtani34, Tomoharu Sugie35, Anna Ehinger36, Carlos
Castaneda37, Marleen Kok38, Heather McArthur39, Kalliopi Siziopikou40, Sunil Badve41, Susan
Fineberg42, Allen Gown43, Giuseppe Viale44,45, Stuart J Schmitt46,47, Giancarlo Pruneri48,49,
Frederique Penault-Llorca49,50, Stephen Hewitt51, E Aubrey Thompson52, Kimberly Allison53,
William F Symmans54, Andrew M Bellizzi55, Edie Brogi56, David Moore57, Denis Larsimont58,
Deborah A Dillon56, Alexander Lazar52, Huangchun Lien59, Matthew P Goetz60, Glenn Broeckx61,
Khalid El Bairi62, Nadia Harbeck63, Ashley Cimino-Mathews64, Christos Sotiriou65, Sylvia
Adams66, Shi-wei Liu67, Sibylle Loibl68, I-Chun Chen69, Sunil R Lakhani71, Jonathan W Juco71, ,
Carsten Denkert72, Elizabeth F Blackley73, Sandra Demaria7, Roberto Leon-Ferre74, Oleg Gluz75,
Dimitrios Zardavas76, Kenneth Emancipator71, Scott Ely77, Sherene Loi73,78, Roberto Salgado78,79,
Melinda Sanders1,26* on behalf of the International Immuno-Oncology Biomarker Working Group.

1Breast Cancer Research Program, Vanderbilt University Medical Center, Nashville, USA.
2Department of Pathology, Herlev and Gentofte Hospital, University of Copenhagen, Herlev,
   Denmark.
3Department of Pathology, Fundación Valle del Lili, Cali, Colombia.
Department of Pathology, Yale School of Medicine, New Haven, USA.

Department of Pathology, BC Cancer Agency, Vancouver, Canada

Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, USA.

Biostatistics and Epidemiology Service, Centre de Recherche en Epidémiologie et Santé des Populations, Gustave Roussy, Université Paris-Sud, Villejuif, France.

Leicester Cancer Research Centre, University of Leicester, Leicester, UK.

MRC Toxicology Unit, University of Cambridge, Leicester, UK

Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada.

Department of Surgical Pathology, Zealand University Hospital, Denmark

Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, Australia.

Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.

Department of Pathology, Gustave Roussy, Grand Paris, France.

Ontario Institute for Cancer Research, Toronto, Canada

Institute of Genetics and Molecular Medicine, Edinburgh, UK

Department of Pathology, St Vincent's University Hospital and University College Dublin, Dublin, Ireland.

HistoGeneX NV, Antwerp, Belgium

AZ Sint-Maarten Hospital, Mechelen, Belgium.

Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.

Medical Oncology 2, Istituto Oncologico Veneto - IRCCS, Padova, Italy.

Department of Pathology, Insitut Curie, Paris, France.

International Agency for Research on Cancer (IARC), World Health Organization, Lyon, France.
24Department of Pathology, Matsuyama Shimin Hospital, Matsuyama, Japan.

25Department of Medicine, Vanderbilt University Medical Center, Nashville, USA.

26Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, USA.

27Department of Cellular Pathology, North Bristol NHS Trust, Bristol UK

28Translational Health Sciences, University of Bristol, UK.

29Department of Pathology, Sanatorio Mater Dei, Buenos Aires, Argentina.

30Department of Pathology, Hospital de Oncología María Curie, Buenos Aires, Argentina

31Department of Pathology, University of São Paulo, São Paulo, Brazil.

32Department of Pathology, Universidad de La Frontera, Temuco, Chile.

33Department of Pathology, Fudan University Shanghai Cancer Centre, Shanghai, China.

34Department of Histopathology, Manipal Hospitals Dwarka, New Delhi.

35Breast Surgery, Kansai Medical University Hospital, Hirakata, Japan.

36Department of Clinical Genetics and Pathology, Skane University Hospital, Lund University, Lund, Sweden.

37Department of Research, Instituto Nacional de Enfermedades Neoplásicas, Lima, Perú.

38Divisions of Medical Oncology, Tumor Biology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.

39Medical Oncology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, USA.

40Department of Pathology, Breast Pathology Section, Northwestern University, Chicago, USA.

41Department of Pathology and Laboratory Medicine, Indiana University, Indianapolis, USA.

42Department of Pathology, Montefiore Medical Center, Bronx, USA.

43PhenoPath Laboratories, Seattle, USA.
44Department of Pathology, Istituto Europeo di Oncologia IRCCS, Milan, Italy.
45University of Milan, Milan, Italy.
46Department of Pathology, Dana-Farber Cancer Institute, Boston, USA.
47Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, USA.
48Department of Pathology, IRCCS Fondazione Instituto Nazionale Tumori, Milan, Italy.
49Department of Biology and Pathology, Centre Jean Perrin, Clermont Ferrand, France.
50UMR INSERM 1240, Université Clermont Auvergne, Clermont Ferrand, France.
51Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA.
52Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, USA.
53Department of Pathology, Stanford University, Stanford, USA.
54Department of Pathology, Division of Pathology and Laboratory Medicine, The University of Texas, MD Anderson Cancer Center, Houston, United States.
55Department of Pathology, University of Iowa Hospitals and Clinics, Iowa City, USA.
56Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, USA.
57Department of Pathology, University College London Cancer Institute, University College London, London, UK.
58Department of Pathology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
59Graduate Institute of Pathology, National Taiwan University, Taipei, Taiwan.
60Department of Oncology, Mayo Clinic, Rochester, USA.
61Department of Pathology, University Hospital Antwerp, Belgium.
62Cancer Biomarkers Working Group, Faculty of Medicine and Pharmacy, Mohamed 1st University, Oujida, Morocco.
63Breast Center, Dept. OB&GYN and CCC (LMU), University of Munich, Munich, Germany.
64Departments of Pathology and Oncology, The Johns Hopkins Hospital, Baltimore, USA.
65Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels.
66Perlmutter Cancer Center, New York University Medical School, New York, USA.
67Sichuan Cancer Hospital, Chengdu, China.
68German Breast Group, Neu-Isenburg, Germany.
69Department of Oncology, National Taiwan University, Taipei, Taiwan.
70Faculty of Medicine, The University of Queensland, Centre for Clinical Research, Royal Brisbane and Women's Hospital, Herston, Australia.
71Translational Medicine, Merck & Co, Inc, Kenilworth, USA.
72Institute of Pathology, Universitätsklinikum Gießen und Marburg GmbH, Standort Marburg and Philipps-Universität Marburg, Marburg, Germany.
73Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
74Department of Radiation Oncology, Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, USA.
75Johanniter GmbH - Evangelisches Krankenhaus Bethesda Mönchengladbach, West German Study Group, Mönchengladbach, Germany.
76Oncology Clinical Development, Bristol-Myers Squibb, Princeton, USA.
77Translational Medicine, Bristol-Myers Squibb, Princeton, USA.
78Division of Research and Cancer Medicine, Peter MacCallum Cancer Centre, University of Melbourne, Victoria, Australia.
7Department of Pathology, GZA-ZNA Hospitals, Antwerp, Belgium.

*Correspondence to: Paula Gonzalez Ericsson, Breast Cancer Research Program, Vanderbilt University Medical Center, Nashville, USA. E-mail: paula.i.gonzalez.ericsson@vumc.org
Melinda Sanders, Department of Pathology, Microbiology and Immunology, and Breast Cancer Research Program, Vanderbilt University Medical Center, Nashville, USA. E-mail: Sanders, Melinda E-mail: melinda.sanders@vumc.org

Short running title: Implementation of PD-L1 and TILs as immuno-oncology biomarkers for breast cancer.

Conflicts of interest: ACM is a consultant and reports research grant support from Bristol-Meyers Squibb. AE is on the Roche advisory board and is a lecturer paid by Roche, Amgen and Novartis. AIH reports honoraria from Chugai Pharmaceutical, Taiho Pharmaceutical and Novartis Pharma. CQ has received speaker fees from Roche and Genomic Health. DLR is on the advisory board for Amgen, Astra Zeneca, Cell Signaling Technology, Cepheid, Daiichi Sankyo, GSK, Konica Minolta, Merk, Nanostrings, Perkin Elmer, Roche, Ventana and Ultivue; is a consultant for Biocept, NextCure, Odonate and Sanofi; is a founder and equity hilder of PixelGear; reports research support from Astra Zeneca, Cepheid, Navigate BioPharma, NextCure, Lilly and Ultivue; instrument support from Ventana, Akoya perkin Elmer and Nanonstrings; travel honorarium from Bristol-Myers Squibb; and royalties from Rarecyte. DZ is an employee of Bristol-Myers Squibb with stock ownership. FPL reports honoraria and funding form Astra Zeneca, BMS, MERCK,
Nanostring, Pfizer and Roche. HM is a consultant for Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Genentech/Roche, Immunomedics, Merck, OBI Pharma, Pfizer, Puma, Spectrum Pharmaceuticals, Syndax Pharmaceuticals, Peregrine, Calithera, Daiichi-Sankyo and TapImmune; and has research supported by Bristol-Myers Squibb, MedImmune, LLC AstraZeneca, BTG and Merck. JA is an advisor for AstraZeneca, Bayer, Bristol Myers Squibb, MSD, Roche and Diaceutics, and reports research funding from MSD, Bayer, and Pierre Fabre. JB is a consultant for Insight Genetics Inc, BioNTech AG, Biotheranostics Inc, Pfizer, Rna Diagnostics Inc and oncoXchange; reports honoraria from NanoString Technologies, Oncology Education and Biotheranostics Inc; research funding from Thermo Fisher Scientific, Genoptix, Agendia, NanoString Technologies Inc, Stratifyer GmbH and Biotheranostics Inc; travel expenses from Biotheranostics Inc and NanoString Technologies Inc; and patents regarding biomarker evaluation and gene signatures to predict response to treatment. JMB reports research support from Genentech/Roche, Bristol Myers Squibb and Incyte Corporation, has received consulting expert witness fees from Novartis and is an inventor on provisional patents regarding immunotherapy targets and biomarkers in cancer. JJ is a full-time employee of Merck & Co., Inc. and owns stock in Merck & Co., Inc., Regeneron and Illumina. KE is a full-time employee in Merck & Co., Inc. and owns stock in that company as well as Bayer AG and Johnson & Johnson; his wife is a full-time employee of Bristol Myers Squibb and owns stock in that company. KS reports one-time honorarium from Roche Ventana. MK is on the Advisory board for BMS and Daiichi. OG reports travel support from Roche, Celgene, Daiichi and honoraria advisory boards form Roche, Celgene, Novartis, Pfizer, Lilly, GHI, Nanostring, Amgen and MSD. RLF reports travel Support from Immunomedics. RS reports research funding from Roche Genentech, Puma Biotechnology and Merck, honoraria for consulting for BMS and travel funding from Roche Genentech, Merck and
Astra Zeneca. SE is an employee of Bristol-Myers Squibb with stock ownership. TON has a proprietary interest in the PAM50 subtype classifier form Bioclassifer LLC, Nanostring Technologies.

**Acknowledgements:** The authors recognize the members of the International Immuno-Oncology Biomarker Working Group for reviewing and providing critical feedback on the manuscript. RS is supported by the Breast Cancer Research Foundation, New York, US. SL is supported by the National Breast Cancer Foundation of Australia Endowed Chair and the Breast Cancer Research Foundation, New York.

**Author contribution statement:** RS conceived the presented idea, PGE did the literature search and took the lead in writing the manuscript, with the guidance of RS and MS. All authors provided critical feedback and helped shape the manuscript.

**Disclaimer:** This work includes contributions from, and was reviewed by, individuals who are personnel of Bristol-Myers Squibb, Merck & Co, Inc and the International Agency for Research on Cancer / World Health Organization. The content is solely the responsibility of the authors and does not necessarily represent the official views or policy of Bristol-Myers Squibb, Merck & Co, Inc or International Agency for Research on Cancer / World Health Organization.